 |
 |
| Cognoptix says that its "SAPPHIRE II" optical system uses time-correlated laser fluorescence decay to detect beta-amyloid plaques that are a biomarker for Alzheimer's. Unlike other techniques, it is thought that the method is able to spot these proteins in the lens of the eye possibly decades before the onset of any Alzheimer's-related symptoms. Cognoptix is set to begin a pivotal trial of the system in 2021, with FDA approval slated for 2023 if the trial proves successful. Photo: Cognoptix. |
| © 2024 SPIE Europe |
|
